Pharming Group N.V. (PHAR) Q3 2026 Earnings — Mixed Results

Screener

Reported October 27, 2026 · Before market open

Revenue$117.6MIn line

EPS$0.30Beat by $0.15

Revenue estimate$117.6M

EPS estimate$0.15

Next report

Date not yet announced

Versus estimates

Revenue

Q3 2026$117.6MIn line

Q2 2026$90.2MMiss by $9.3M Q1 2026$72.4MMiss by $19.6M Q4 2025$106.5MMiss by $5.3M Q3 2025$97.3MMiss by $932.8K Q2 2025$110.6MBeat by $30.4M

Diluted EPS

Q3 2026$0.30Beat by $0.15

Q2 2026$0.02Miss by $0.04 Q1 2026-$0.07Miss by $0.12 Q4 2025$0.07Miss by $0.08 Q3 2025$0.10Beat by $0.05 Q2 2025$0.06Beat by $0.16

FAQ

When did Pharming Group N.V. report Q3 2026 earnings?: Pharming Group N.V. (PHAR) reported Q3 2026 earnings on October 27, 2026 before market open.
What were Pharming Group N.V.'s Q3 2026 revenue and EPS?: Pharming Group N.V. reported revenue of $117.6M and eps of $0.30 for Q3 2026.
Did Pharming Group N.V. beat estimates in Q3 2026?: Revenue beat the consensus estimate of $117.6M by -. EPS beat the consensus estimate of $0.15 by $0.15.
How did Pharming Group N.V.'s Q3 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 20.9% from $97.3M a year earlier and eps grew 200.0% from $0.10.

Ask the moment Pharming Group N.V. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk